Acute Pancreatitis Clinical Trial
Official title:
Drainage and Debridement of Local Complications of Acute Pancreatitis: A Single-center Real-world Prospective Study
NCT number | NCT06023771 |
Other study ID # | K4433 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | October 2023 |
Est. completion date | December 2026 |
Strategies for invasive intervention in acute pancreatitis include sequential or combined use of multiple drainage and debridement modalities. The more widely used is the step-up approach, which requires an individualized and multidisciplinary (internal medicine, interventional radiology, endoscopy, surgery, critical care medicine, and nutritionists) approach. The available evidence from randomized controlled studies is from highly selected subject populations, and it is unclear whether the results can be applied to complex clinical situations in real clinics, and the optimal strategy for drainage of peripancreatic lesions in different patients still needs to be evaluated in the real world. This study intends to establish a prospective single-center cohort for real-world analysis to collect comprehensive clinic information and clinical outcomes, to evaluate the effectiveness and safety of existing intervention strategies, especially the timing and modality of interventions, in real-world clinical practice, and to explore the key factors affecting patient prognosis.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 2026 |
Est. primary completion date | October 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Admission diagnosis of acute pancreatitis; - Localized complications confirmed by imaging examinations; - Voluntary participation in the study and signing of an informed consent form. Exclusion Criteria: - Improved with conservative treatment without invasive interventions for local complications during hospitalization. |
Country | Name | City | State |
---|---|---|---|
China | Peking Union Medical College Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking Union Medical College Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Major complications or death | A composite of major complications (i.e., new-onset multiple organ failure or systemic complications, enterocutaneous fistula or perforation of a visceral organ requiring intervention, or intraabdominal bleeding requiring intervention) or death during admission or during the 6 months after discharge. | Day 1 from admission until 6 months after discharge | |
Secondary | Organ failure | New-onset ( not present at any time in the 24 hours before first intervention) pulmonary failure, circulatory failure, or renal failure | Day 1 from admission until 6 months after discharge | |
Secondary | Systemic complication | New-onset ( not present at any time in the 24 hours before first intervention) systematic complications such as disseminated intravascular coagulation, severe metabolic disturbance, and gastrointestinal bleeding | Day 1 from admission until 6 months after discharge | |
Secondary | Enterocutaneous fistula | Secretion of fecal material from a percutaneous drain or drainage canal after removal of drains or from a surgical wound, either from small or large bowel; confirmed by imaging or during surgery | Day 1 from admission until 6 months after discharge | |
Secondary | Perforation of visceral organ | Perforation requiring surgical, radiologic, or endoscopic intervention | Day 1 from admission until 6 months after discharge | |
Secondary | Intraabdominal bleeding | Requiring surgical, radiologic, or endoscopic intervention | Day 1 from admission until 6 months after discharge | |
Secondary | Pancreatic fistula | Output, through a percutaneous drain or drainage canal after removal of drains or from a surgical wound, of any measurable volume of fluid with an amylase content >3 times the serum amylase level | Day 1 from admission until 6 months after discharge | |
Secondary | New-onset diabetes | Insulin or oral antidiabetic drugs required 6 mo after discharge; this requirement was not present before onset of pancreatitis | Day 1 from admission until 6 months after discharge | |
Secondary | Use of pancreatic enzymes | Oral pancreatic-enzyme supplementation required to treat clinical symptoms of steatorrhea 6 mo after discharge; this requirement was not present before onset of pancreatitis | Day 1 from admission until 6 months after discharge | |
Secondary | Length of hospitalization | Total days of hospitalization for the management of acute pancreatitis | Day 1 from admission until the 1 day of discharge | |
Secondary | Length of intesive care | Total days in intesive care unit for the management of acute pancreatitis | Day 1 from admission until the 1 day of discharge | |
Secondary | Total direct medical costs and indirect costs | Total direct medical costs and indirect costs during admission | Day 1 from admission until the 1 day of discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05410795 -
Establishment and Verification of Pancreatic Volume Formula Based on Imaging
|
||
Recruiting |
NCT04195347 -
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
|
Phase 1/Phase 2 | |
Completed |
NCT04735055 -
Artificial Intelligence Prediction for the Severity of Acute Pancreatitis
|
||
Completed |
NCT02928718 -
The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
|
||
Terminated |
NCT02885441 -
Treatment of Acute Pancreatitis With Ketorolac
|
Phase 4 | |
Completed |
NCT02563080 -
Pancreatic Exocrine Insufficiency in Acute Pancreatitis
|
||
Recruiting |
NCT01626911 -
Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis
|
N/A | |
Completed |
NCT01507766 -
The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis
|
Phase 4 | |
Completed |
NCT04901949 -
The Course of Acute Pancreatitis in Patients With Different BMI Groups
|
||
Recruiting |
NCT04814693 -
Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis
|
N/A | |
Completed |
NCT02743364 -
Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
|
Phase 2 | |
Recruiting |
NCT05281458 -
Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections
|
N/A | |
Not yet recruiting |
NCT04990336 -
Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis
|
N/A | |
Not yet recruiting |
NCT03259880 -
Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals
|
N/A | |
Completed |
NCT02543658 -
Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension
|
Phase 2 | |
Not yet recruiting |
NCT05501314 -
Remote Home Monitoring Acute Pancreatitis
|
N/A | |
Completed |
NCT02897206 -
Imipenem Prophylaxis in Patients With Acute Pancreatitis
|
Phase 4 | |
Recruiting |
NCT03634787 -
Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
|
||
Active, not recruiting |
NCT04989166 -
Effect of Nano-curcumin Supplementation in Acute Pancreatitis
|
N/A | |
Recruiting |
NCT05613673 -
Prognostic Value of Different Nutritional Screening Tools in Acute Pancreatitis
|